Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorthalidone
Drug ID BADD_D00448
Description Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. Chlorthalidone improves blood pressure and swelling by preventing water absorption from the kidneys through inhibition of the Na+/Cl− symporter in the distal convoluted tubule cells in the kidney. The exact mechanism of chlorthalidone's anti-hypertensive effect is under debate, however, it is thought that increased diuresis results in decreased plasma and extracellular fluid volume, decreased cardiac output and therefore overall reduction in blood pressure.[A176324] Chlorthalidone is considered first-line therapy for management of uncomplicated hypertension as there is strong evidence from meta-analyses that thiazide diuretics such as chlorthalidone reduce the risk of stroke, myocardial infarction, heart failure, and cardiovascular all-cause mortality in patients with hypertension.[A173863] In particular, the ALLHAT trial confirmed the role of thiazide diuretics as first-line therapy and demonstrated that chlorthalidone had a statistically significant lower incidence of stroke and heart failure when compared to [DB00722], [DB00381], or [DB00590].[A173884, A173887] Further studies have indicated that low-dose thiazides are as good as, and in some secondary endpoints, better than β-blockers, ACE inhibitors, Calcium Channel Blockers or ARBs. Chlorthalidone has been shown to have a number of pleiotropic effects that differentiate it from other diuretics such as [DB00999]. In addition to its antihypertensive effects, chlorthalidone has also been shown to decrease platelet aggregation and vascular permeability, as well as promote angiogenesis in vitro, which is thought to be partly the result of reductions in carbonic anhydrase–dependent pathways. These pathways may play a role in chlorthalidone's cardiovascular risk reduction effects.[A176330]
Indications and Usage For management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
Marketing Status Prescription; Discontinued
ATC Code C03BA04
DrugBank ID DB00310
KEGG ID D00272
MeSH ID D002752
PubChem ID 2732
NDC Product Code 50090-3910; 50090-5860; 70934-470; 57664-649; 68071-4018; 70199-017; 55700-586; 53808-1105; 66689-345; 51079-058; 50090-4223; 71610-472; 44657-0058; 70600-008; 65162-247; 29300-334; 50090-3190; 62135-505; 71205-592; 68382-971; 70934-938; 50090-5085; 63629-6347; 16714-801; 62512-0026; 44657-0057; 63629-8762; 70518-1376; 0378-0222; 59746-761; 43598-720; 53747-063; 63629-8761; 63629-2465; 71335-0906; 71335-1829; 29300-333; 59746-760; 50090-3161; 75834-110; 70199-001; 50268-167; 69037-0056; 71610-029; 0378-0213; 70934-562; 27241-217; 16714-128; 67877-697; 57664-648; 70518-2552; 64980-304; 66689-346; 67877-696; 64980-303; 71610-021; 68382-970; 70518-2690; 63629-8480; 75834-109; 65162-250; 50090-5643; 50090-5183; 55289-067; 16714-129; 53002-1623; 71335-1708; 71335-0624; 27241-216; 0904-6900; 50090-5044; 68071-5219; 16714-800; 68071-4636; 43598-719; 63629-5259; 50090-5541; 62135-506; 60687-317; 70771-1369; 70771-1370; 44657-0034; 52562-003
Synonyms Chlorthalidone | Chlorphthalidolone | Phthalamudine | Oxodoline | Chlortalidone | Hygroton | Thalitone
Chemical Information
Molecular Formula C14H11ClN2O4S
CAS Registry Number 77-36-1
SMILES C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.0020.000769%
Abdominal pain upper07.01.05.003--
Agranulocytosis01.02.03.001--Not Available
Alkalosis hypochloraemic14.01.02.003--Not Available
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.0010.001794%Not Available
Back pain15.03.04.0050.001025%
Blood creatinine increased13.13.01.0040.001025%
Blood magnesium decreased13.11.01.0080.000512%Not Available
Blood pressure increased13.14.03.0050.000769%Not Available
Blood uric acid increased13.02.04.001--Not Available
Bradycardia02.03.02.0020.000512%Not Available
Cholestasis09.01.01.001--Not Available
Coagulopathy01.01.02.0010.000769%Not Available
Confusional state19.13.01.001;
Cutaneous vasculitis24.05.02.004;; Available
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages